Targets › FOXO1
1 program from 1 company in 4 trials: 2 Phase 3, 1 Phase 2, 1 Phase 1; Oncology; next expected readout Mar 2027.
Transcription factor that is the main target of insulin signaling and regulates metabolic homeostasis in response to oxidative stress. Binds to the insulin response element (IRE) with consensus sequence 5'-TT[G/A]TTTTG-3' and the related Daf-16 family binding element (DBE) with consensus sequence 5'-TT[G/A]TTTAC-3'. Activity suppressed by insulin. (UniProt, Q12778)
Open in Phaseline: the race on FOXO1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Suzhou Suncadia Biopharmaceuticals | SHR-A2102 for Injection Forkhead box protein O1 (FOXO1) inhibitor | FOXO1 | Phase 3 | Recurrent Cervical Cancer; Locally Advanced or Metastatic Urothelial Carcinoma; Muscular Invasive Bladder Cancer (MIBC); Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Mar 2027 |
Recurrent Cervical Cancer (1) Locally Advanced or Metastatic Urothelial Carcinoma (1) Muscular Invasive Bladder Cancer (MIBC) (1) Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.